We believe Vertex is in strong financial health, given its robust cash flow generation and low debt. At the end of 2024, Vertex held about $11.2 billion in cash and equivalents.

Vertex Pharmaceuticals' shares dropped due to poor first-quarter results. Vertex's business and prospects remain attractive.

Shares in Vertex have soared after the company announced that tens of thousands of cystic fibrosis (CF) patients could benefit from treatment for the first time. The company is a pioneer in ...

Vertex Pharmaceuticals is diversifying its already strong lineup of medicines. Axsome Therapeutics has multiple clinical and ...

Together these drugs cover the CFTR mutations seen in around half of all CF patients. The next phase of Vertex is focused on the roll-out of its new triple Kaftrio (tezacaftor, ivacaftor and ...

CRISPR Therapeutics partnered with big biotech Vertex Pharmaceuticals ( VRTX 3.40%) on Casgevy. Although Vertex takes a ...

We recently published a list of 15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies In this article, we ...

Today Vertex CF medicines are treating over 68,000 people ... Mall, M.D., in this press release, statements regarding the expected eligible patient population for ALYFTREK, if approved, and ...

Vertex famously dominates the CF area, and its current medicines can treat about 90% of patients with this rare disease. It was developing VX-522 for some patients who are not eligible for the ...

Vertex Pharmaceuticals Incorporated ... regimen that is far more convenient for patients. Importantly, it covers 31 additional rare mutations of CF for which no previous treatment existed.